Study Links Semaglutide to Eye Condition NAION
Study Links Semaglutide to Eye Condition NAION

Study Links Semaglutide to Eye Condition NAION

News summary

A study led by Mass Eye and Ear researchers revealed that patients prescribed semaglutide for diabetes or weight loss, marketed as Ozempic or Wegovy, faced a higher risk of developing NAION, a rare eye condition leading to potential blindness. Those with diabetes or obesity on semaglutide were over four and seven times more likely to be diagnosed with NAION, respectively. Despite its rarity, NAION's risk should be discussed between patients and physicians considering these drugs. NAION, caused by reduced blood flow to the optic nerve, lacks effective treatments and often results in irreversible vision loss. Novo Nordisk, the drug manufacturer, emphasized the need for further research to establish a causal link between semaglutide and NAION.

Story Coverage
Bias Distribution
100% Left
Information Sources
372f1eb9-53ba-4c9c-bd38-30c47db3342a
Left 100%
Coverage Details
Total News Sources
1
Left
1
Center
0
Right
0
Unrated
0
Last Updated
108 days ago
Bias Distribution
100% Left
Related News
Daily Index

Negative

21Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage

Related Topics

Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Related News
Recommended News